(WAT) Waters - Ratings and Ratios

Waters Corporation (NYSE:WAT) is a leading global provider of analytical workflow solutions, operating in Asia, the Americas, and Europe. The company is divided into two main segments: Waters and TA. It specializes in the design, manufacture, sale, and servicing of high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) systems, as well as mass spectrometry (MS) technology and related consumables. These include chromatography columns, other consumable products, and post-warranty service plans. Additionally, the company offers thermal analysis, rheometry, and calorimetry instruments, along with software-based products that integrate with its own and third-party instruments.

The company’s MS technology is widely used in drug discovery and development, including clinical trial testing, protein analysis in disease processes, nutritional safety analysis, and environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are utilized to evaluate the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare applications, as well as life science research. Customers include clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental entities, primarily in research and development, quality assurance, and laboratory settings. Founded in 1958, Waters Corporation is headquartered in Milford, Massachusetts.

Based on the provided data, the 3-month forecast for Waters Corporation (NYSE:WAT) suggests the following trends:

- Technical Outlook: The stock is currently trading below its SMA 20, SMA 50, and SMA 200, indicating bearish momentum. The average true range (ATR) of 15.45 suggests moderate volatility, with potential resistance at SMA 50 (364.53) and SMA 200 (357.62). - Fundamental Outlook: With a P/E of 29.95 and forward P/E of 24.75, the stock is pricey but indicates expectations of future earnings growth. The P/B ratio of 10.45 reflects a premium valuation, while the P/S ratio of 6.46 highlights strong revenue multiples. The ROE of 34.88% underscores efficient equity utilization. - 3-Month Forecast: Expect sideways to downward movement in the near term, with potential support near 300.00. The stock may face resistance at 341.25 (SMA 20) and 364.53 (SMA 50). Fundamental strength could offset technical weakness if earnings exceed expectations.